PULSE Challenge: Selection and screening of antibody based drugs
March 17, 2025 @ 13:00 – 14:00 CET
This presentation will provide an overview of the selection and screening processes, as well as future challenges for antibody-based drugs. It will be exemplified with data from one of Alligator Bioscience’s bispecific antibody drug candidates, ATOR-4066. ATOR-4066 is a novel bispecific antibody constructed in the RUBY™ format using Alligator Bioscience’s Neo-X-Prime platform. It targets the tumor-associated antigen CEA (CEACAM5) on tumor cells and CD40 on myeloid cells. ATOR-4066 is designed to induce efficient CEA-conditional activation of myeloid cells, facilitate the uptake of neoantigen-containing tumor-derived material, and subsequently drive the cross-priming of tumor-specific T cells, resulting in long-lasting anti-tumor activity.
The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE, that will train 48 future leaders in life sciences. The program focuses on innovative, fundamental and translational research carried out in supportive and diverse academic and industrial environments, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE
On-line event via Zoom
Presenter:
Dr Peter Ellmark, PhD
Chief Scientific Officer
Alligator bioscience, Lund, Sweden
Abstract:
Antibody-based drugs have revolutionized the treatment landscape for numerous serious conditions, with a global market size exceeding $250 billion. The success of these drugs can be attributed to their high specificity and versatility. Critical to the successful development of antibody-based drugs is the appropriate selection and screening methodology, which ensures that drug candidates meet all key criteria for successful development.
A short speaker biography:
Peter Ellmark joined Alligator Bioscience in 2008 and serves as Chief Scientist. He holds a PhD and an adjunct professorship in Immunotechnology at Lund University and has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies, in particular CD40 and 4-1BB targeting therapies, for tumor directed immunotherapy of cancer.
Google Calendar 
